BridgeBio Pharma/$BBIO
BridgeBio Pharma shares are trading higher following positive commentary about a potential breakout in the biotech sector.
22 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BridgeBio Pharma
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Ticker
$BBIO
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
728
ISIN
US10806X1028
Website
BridgeBio Pharma Metrics
BasicAdvanced
$8.7B
-
-$3.54
1.08
-
Price and volume
Market cap
$8.7B
Beta
1.08
52-week high
$46.43
52-week low
$21.72
Average daily volume
3.1M
Financial strength
Current ratio
5.139
Quick ratio
4.312
Long term debt to equity
-113.4
Total debt to equity
-113.4
Interest coverage (TTM)
-5.67%
Profitability
EBITDA (TTM)
-662.65
Gross margin (TTM)
95.35%
Net profit margin (TTM)
-524.25%
Operating margin (TTM)
-524.60%
Effective tax rate (TTM)
-0.17%
Revenue per employee (TTM)
$180,000
Management effectiveness
Return on assets (TTM)
-48.27%
Return on equity (TTM)
50.59%
Valuation
Price to revenue (TTM)
68.181
Price to book
-5.29
Price to tangible book (TTM)
-5.21
Price to free cash flow (TTM)
-17.053
Free cash flow yield (TTM)
-5.86%
Free cash flow per share (TTM)
-269.63%
Growth
Revenue change (TTM)
-41.71%
Earnings per share change (TTM)
11.20%
3-year revenue growth (CAGR)
21.55%
3-year earnings per share growth (CAGR)
-4.64%
What the Analysts think about BridgeBio Pharma
Analyst ratings (Buy, Hold, Sell) for BridgeBio Pharma stock.
Bulls say / Bears say
BridgeBio Pharma's lead drug, Attruby (acoramidis), received FDA approval in November 2024 for treating transthyretin amyloid cardiomyopathy (ATTR-CM), positioning it as a strong competitor to Pfizer's Vyndamax. (nasdaq.com)
The company reported $36.7 million in net product revenue for Attruby in its first full quarter, with over 2,000 unique patient prescriptions written by more than 750 prescribers as of April 2025. (financialcontent.com)
Analysts have raised their price targets for BBIO, with Wells Fargo increasing it to $76, reflecting confidence in the company's growth prospects. (reporter.am)
A major shareholder sold $205.2 million worth of BBIO stock in May 2025, which could indicate potential concerns about the company's future performance. (techdows.com)
The company's revenue for Q3 2024 was $2.73 million, missing analysts' expectations by $0.65 million, and operating expenses increased significantly, leading to a net loss of $162 million for the quarter. (nasdaq.com)
BridgeBio faces competition from established players like Pfizer, whose Vyndamax generated $3.3 billion in global revenue in 2023, potentially impacting Attruby's market share. (nasdaq.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
BridgeBio Pharma Financial Performance
Revenues and expenses
BridgeBio Pharma Earnings Performance
Company profitability
BridgeBio Pharma News
AllArticlesVideos
It is time for a move higher in biotech, says Mizuho's Jared Holz
CNBC Television·3 days ago
BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty
GlobeNewsWire·1 week ago
BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BridgeBio Pharma stock?
BridgeBio Pharma (BBIO) has a market cap of $8.7B as of July 10, 2025.
What is the P/E ratio for BridgeBio Pharma stock?
The price to earnings (P/E) ratio for BridgeBio Pharma (BBIO) stock is 0 as of July 10, 2025.
Does BridgeBio Pharma stock pay dividends?
No, BridgeBio Pharma (BBIO) stock does not pay dividends to its shareholders as of July 10, 2025.
When is the next BridgeBio Pharma dividend payment date?
BridgeBio Pharma (BBIO) stock does not pay dividends to its shareholders.
What is the beta indicator for BridgeBio Pharma?
BridgeBio Pharma (BBIO) has a beta rating of 1.08. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.